Implementing amobile stroke unit program in the united states: Why, how, and how much?

JAMA Neurology

Volumn 72, Issue 2, 2015, Pages 229-234

  Rajan, Suja ^a   Baraniuk, Sarah ^a   Parker, Stephanie ^b   Wu, Tzu Ching ^b   Bowry, Ritvij ^c   Grotta, James C ^c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; EARLY INTERVENTION; EMERGENCY HEALTH SERVICE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; MOBILE STROKE UNIT; NEUROLOGIST; PATIENT CARE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TELEMEDICINE; UNITED STATES; CLINICAL TRIAL (TOPIC); ECONOMICS; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; PROCEDURES; PROGRAM DEVELOPMENT; STANDARDS; STROKE;

CLINICAL TRIALS AS TOPIC; EARLY MEDICAL INTERVENTION; HUMANS; MOBILE HEALTH UNITS; PROGRAM DEVELOPMENT; STROKE; UNITED STATES;

EID: 84923035768     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.3618     Document Type: Article

References (26)

1. Jauch EC, Saver JL, Adams HP Jr, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587.
3. Hacke W, Donnan G, Fieschi C, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.
4. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.
5. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology. 2000;55(11): 1649-1655.
6. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40(6):2079-2084.
7. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-2488.
8. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750-758.
9. Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 2014;311(16):1632-1640.
10. Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol. 2012;11(5):397-404.
11. Ebinger M, Winter B, Wendt M, et al; STEMO Consortium. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA. 2014;311(16):1622-1631.
12. Ciccone A, Valvassori L; SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(25): 2433-2434.
13. Broderick JP, Palesch YY, Demchuk AM, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893-903.
14. Kidwell CS, Jahan R, Gornbein J, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368(10):914-923.
15. Wu TC, Nguyen C, Ankrom C, et al. Prehospital utility of rapid stroke evaluation using in-ambulance telemedicine: a pilot feasibility study. Stroke. 2014; 45(8):2342-2347.
16. Johansson T, Wild C. Telemedicine in acute stroke management: systematic review. Int J Technol Assess Health Care. 2010;26(2):149-155.
17. Ebinger M, Wendt M, Rozanski M, et al. Golden hour-thrombolysis by starting treatment before hospital arrival: the Pre-hospital Acute Neurological Treatment and Optimization of Medical Care in Stroke Study (PHANTOM-S) [abstract 104]. Stroke. 2014;45: A104.
18. Wahlgren N, Ahmed N, Dávalos A, et al; SITS Investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646): 1303-1309.
19. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306-313.
20. Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011. Rockville, MD: Agency for Health Care Policy & Research; 2013. HCUP statistical brief 160.
21. Trogdon JG, Finkelstein EA, Nwaise IA, Tangka FK, Orenstein D. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract. 2007;8(3):234-242.
22. Cohen JW, Krauss NA. Spending and service use among people with the fifteen most costly medical conditions, 1997. Health Aff (Millwood). 2003;22(2):129-138.
23. Ovbiagele B, Goldstein LB, Higashida RT, et al; American Heart Association Advocacy Coordinating Committee and Stroke Council. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013;44(8): 2361-2375.
24. Fagan SC, Morgenstern LB, Petitta A, et al; NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology. 1998;50(4):883-890.
25. Tan Tanny SP, Busija L, Liew D, Teo S, Davis SM, Yan B. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center. Stroke. 2013;44(8):2269-2274.
26. Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3-to 4.5-hour time window for acute ischemic stroke. Stroke. 2011;42(8):2257-2262.